Get the Stockscreener App
4.845
2.22%
0.115
Rocket Pharmaceuticals Inc stock is traded at $4.845, with a volume of 779.05K.
It is up +2.22% in the last 24 hours and up +47.85% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$4.73
Open:
$4.82
24h Volume:
779.05K
Relative Volume:
0.32
Market Cap:
$524.93M
Revenue:
-
Net Income/Loss:
$-223.12M
P/E Ratio:
-2.411
EPS:
-2.0095
Net Cash Flow:
$-190.49M
1W Performance:
-5.39%
1M Performance:
+47.85%
6M Performance:
+48.76%
1Y Performance:
-44.81%
1-Day Range:
$4.77
$4.93
1-Week Range:
$4.625
$5.45
52-Week Range:
$2.19
$8.89
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
4.835 | 513.53M | 0 | -223.12M | -190.49M | -2.0095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.59 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.23 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
707.13 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.59 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
288.12 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-20-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-25-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Suvretta Capital Management LLC Cuts Position in Rocket Pharmaceuticals, Inc. $RCKT - MarketBeat
Rocket Pharmaceuticals, Inc. $RCKT Holdings Trimmed by Prosight Management LP - MarketBeat
Chart Watch: Is Rocket Pharmaceuticals Inc forming a bullish divergence2026 Levels & Fast Gain Swing Alerts - baoquankhu1.vn
Insider Buy: Is Rocket Pharmaceuticals Inc part of any ETF2026 Earnings & AI Enhanced Trading Alerts - baoquankhu1.vn
Rocket Pharmaceuticals Enters New Sales Agreement with Cantor Fitzgerald, Terminates Prior Equity Offering Arrangement - Minichart
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 4.8%Should You Sell? - MarketBeat
Rocket Pharmaceuticals Launches New $100M At-The-Market Program - TipRanks
[EFFECT] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Rocket Pharmaceuticals enters $100 million at-the-market offering agreement - Investing.com
Rocket Pharmaceuticals (RCKT) Launches $100 Million Stock Offeri - GuruFocus
Rocket Pharmaceuticals Launches $100 Million ATM Offering With Cantor Fitzgerald - TradingView
According to the latest filing with the U.S. Securities and Exchange Commission, biotechnology company Rocket Pharmaceuticals, Inc. has officially signed an equity sales agreement with renowned financial institution Cantor Fitzgerald & Co. - Bitget
Rocket Pharmaceuticals (RCKT) launches $100M at-the-market stock offering with Cantor - Stock Titan
Form 424B5 ROCKET PHARMACEUTICALS, - StreetInsider
Rocket Pharmaceuticals (RCKT) launches up to $100M ATM offering with Cantor - Stock Titan
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 5.4%What's Next? - MarketBeat
UniQure leads genetic medicine biotech rally after news of Prasad’s exit - BioPharma Dive
Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to Sell at Wall Street Zen - MarketBeat
Short Covering: Is Rocket Pharmaceuticals Inc Equity Warrant attractive for institutional investorsDollar Strength & Low Drawdown Investment Ideas - baoquankhu1.vn
Weekly Recap: Is Rocket Pharmaceuticals Inc showing insider buyingQuarterly Profit Report & Safe Entry Trade Reports - baoquankhu1.vn
Rocket gene therapy among at least 7 PDUFA dates at FDA in March - BioCentury
Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances - Yahoo! Finance Canada
Rocket Pharmaceuticals (NASDAQ: RCKT) files $400M shelf to raise capital - Stock Titan
Goldman Sachs Maintains 'Sell' Rating on RCKT, Raises Price Targ - GuruFocus
The Goldman Sachs Group Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock - MarketBeat
Brokers Set Expectations for RCKT FY2026 Earnings - MarketBeat
Rocket Pharmaceuticals: Advancing Gene Therapy Pipeline and High-Confidence KRESLADI Approval Drive Buy Rating - TipRanks
Chart Watch: Is Rocket Pharmaceuticals Inc showing insider buying2025 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn
Lifesci Capital Upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) to Strong-Buy - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Universal Health (UHS), Crinetics Pharmaceuticals (CRNX) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded to "Hold" at Wall Street Zen - MarketBeat
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - The Globe and Mail
Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring A 71% Upside Potential - DirectorsTalk Interviews
Rocket Pharmaceuticals Q4 2025 Financial Report & Annual ResultsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 14.3% Following Earnings Beat - MarketBeat
Cantor Fitzgerald Raises Rocket Pharmaceuticals (RCKT) Price Tar - GuruFocus
Cantor Fitzgerald Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock - MarketBeat
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of "Hold" from Analysts - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Rocket Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Rocket Pharmaceuticals: Q4 Earnings Snapshot - theheraldreview.com
Rocket Pharmaceuticals' (RCKT) Financial Position at Year-End - GuruFocus
[8-K] ROCKET PHARMACEUTICALS, INC. Reports Material Event | RCKT SEC FilingForm 8-K - Stock Titan
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress - The Joplin Globe
Rocket Pharmaceuticals: Fourth Quarter Financial Results Overview - Bitget
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - The Joplin Globe
Rocket Pharmaceuticals Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Rocket Pharmaceuticals, Inc. $RCKT Shares Acquired by Monaco Asset Management SAM - MarketBeat
Aug Shorts: What are analysts price targets for Rocket Pharmaceuticals Inc2025 Growth vs Value & Fast Entry Momentum Alerts - baoquankhu1.vn
Is Rocket Pharmaceuticals Inc. Equity Warrant stock good for income investors2025 Trade Ideas & Safe Capital Growth Stock Tips - mfd.ru
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):